Clinical Trial Update: Mirdametinib Monotherapy in Adults With Neurofibromatosis 1 (NF1) and Cutaneous Neurofibromas (cNF). [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update indicating recruitment for Mirdametinib monotherapy in adults with Neurofibromatosis type 1 and cutaneous neurofibromas (Phase 1/Phase 2).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cutaneous Neurofibroma
• Neurofibromatosis Type

Drugs mentioned

• Mirdametinib (mirdametinib)

Snippet

Sponsor: Johns Hopkins University | Conditions: NF1, Cutaneous Neurofibroma | Phase 1, Phase 2 | Status: RECRUITING